ERRATUM

Population Pharmacokinetics of Palivizumab, a Humanized Anti-Respiratory Syncytial Virus Monoclonal Antibody, in Adults and Children

Gabriel J. Robbie, Liang Zhao, John Mondick, Genevieve Losonsky, and Lorin K. Roskos

MedImmune, Gaithersburg, Maryland, USA, and Metrum Research Group, Tariffville, Connecticut, USA

Volume 56, no. 9, p. 4927–4936, 2012. Page 4930, right column, line 9: The sentence should read, “Palivizumab clearance maturation was described via the following equation (1a).” See the new reference below.

Page 4931, left column, equation 10: “6,900” should be “16,900.”

Page 4933: Figure 3 should appear as shown below. This corrected version now appears in the online article.

Page 4935, Figure 5 legend: The legend should read, “Group median concentration-time profiles of palivizumab at 15 mg/kg stratified by gestational age and postnatal age cohorts, 0 to 6 months (A), 7 to 12 months (B), and 13 to 24 months (C).”

Page 4936: The following reference should be added.

1a. **Anderson BJ, Allegaert K, Holford NH.** 2006. Population clinical pharmacology of children: modelling covariate effects. *Eur. J. Pediatr.* **165**:819-829.

FIG 3 Simulated concentration-time profiles from the abbreviated 3 monthly 15-mg/kg doses of palivizumab compared with 5 monthly doses. Solid lines are the median predicted concentrations; shaded areas are the 95% prediction intervals.